
Evommune, Inc. ( ($EVMN) ) has shared an announcement. On November 13, 2026, Evommune’s Compensation Committee approved employment-agreement amendments for certain executives, including CEO Luis Peña, CFO Kyle Carver and
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EVMN | Evommune, Inc. | 6.86 | -12.87 | -65.23% |
| Name | Price | % Change | |
|---|---|---|---|
| $6.86 | -65.23% |

Evommune, Inc. ( ($EVMN) ) has shared an announcement. On November 13, 2026, Evommune’s Compensation Committee approved employment-agreement amendments for certain executives, including CEO Luis Peña, CFO Kyle Carver and

Morgan Stanley lowered the firm’s price target on Evommune (EVMN) to $23 from $26 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

The latest announcement is out from Evommune, Inc. ( ($EVMN) ). On November 12, 2026, Evommune reported third-quarter financial results and business updates. The company said its immunology pipeline included

Reports Q3 revenue $0 vs $10M last year. The Company did not generate any revenue for the three and nine months ended September 30, 2026, compared to revenue of $10M

Evommune, Inc. ( ($EVMN) ) just unveiled an update. On November 5, 2026, Evommune announced a pre-recorded webcast on EVO570 and its expanding immunology portfolio. Management was set to discuss

Evommune, Inc. ( ($EVMN) ) has provided an update. On November 4, 2026, Evommune entered an exclusive license agreement with Hinova Pharmaceuticals for worldwide rights outside Greater China to develop,

Evommune (EVMN) announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in

H.C. Wainwright analyst Mitchell Kapoor has reiterated their neutral stance on EVMN stock, giving a Hold rating on October 12. Mitchell Kapoor has given his Hold rating due to a

UBS analyst Alice Nettleton initiated coverage of Evommune (EVMN) with a Neutral rating and $8 price target Following the positive Phase 2a data, UBS views EVO301 as a credible emerging

Evommune, Inc. ( ($EVMN) ) has issued an announcement. On October 1, 2026, Evommune reported Phase 2a proof-of-concept results for EVO301, a long-acting injectable fusion protein targeting IL-18, in a
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| hold | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| hold | Initiated | Oct 11, 2026 | ||||
| buy | Reiterated | Sep 17, 2026 | ||||
| buy | Reiterated | Sep 9, 2026 | ||||
| buy | Reiterated | Sep 9, 2026 | ||||
| buy | Reiterated | Sep 9, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $290.28M | $-1.00 | $1.25M | -0.00 | -1.83 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.